Brokerage firm Prabhudas Lilladher has kept an 'Accumulate' rating for Dr. Reddy’s Laboratories with a price target of ₹1350. The outlook follows a strong Q2 FY27 performance, where the company benefited from US market opportunities and lower R&D costs. Investors are now watching the company’s ability to execute on its specialty product pipeline, particularly its GLP-1 drug portfolio.
Dr. Reddy’s Laboratories recently received a rating update from brokerage firm Prabhudas Lilladher, which maintained an 'Accumulate' stance on the stock with a price target of ₹1350. This assessment followed the company's financial results for the second quarter of the 2027 fiscal year. The company reported an EBITDA of ₹17 billion and an operating margin of 19.1%, supported by specific licensing income and successful exclusivity opportunities in the United States market.
Financial performance in the quarter was bolstered by nearly ₹1.5 billion in milestone and licensing payments. Additionally, a disciplined approach to research and development spending helped sustain profitability during this period. The company is currently shifting its strategy to move away from traditional low-margin generic drugs toward higher-value areas, such as peptides, biosimilars, and GLP-1 products. These specialty segments are considered the next phase of growth for the company, with tangible benefits expected to appear in the second half of fiscal year 2027 and into 2028.
Investors should consider the business risks linked to this strategic transition. While the specialty pipeline offers growth potential, it also carries execution risks. The brokerage firm specifically noted that any potential delay in the re-launch of the Semaglutide product line poses a significant risk to the company’s valuation. Furthermore, the US generic drug market is frequently subject to intense competition and pricing pressure, which can affect profit margins if new product launches are not executed on time or face regulatory hurdles.
Dr. Reddy’s operations in the domestic Indian market and Russia continue to provide a stable foundation, which helps to partially offset the volatility often associated with the US export business. Looking ahead, the company is preparing for upcoming product launches, such as bAbatacept, which is projected to contribute to profitability starting in fiscal year 2028. Moving forward, the most important updates for investors to track will be the timelines for these specific US product launches and the progress of regulatory approvals for its specialty pipeline.